TY - JOUR
T1 - TCEAL1 loss-of-function results in an X-linked dominant neurodevelopmental syndrome and drives the neurological disease trait in Xq22.2 deletions
AU - Hijazi, Hadia
AU - Reis, Linda M
AU - Pehlivan, Davut
AU - Bernstein, Jonathan A
AU - Muriello, Michael
AU - Syverson, Erin
AU - Bonner, Devon
AU - Estiar, Mehrdad A
AU - Gan-Or, Ziv
AU - Rouleau, Guy A
AU - Lyulcheva, Ekaterina
AU - Greenhalgh, Lynn
AU - Tessarech, Marine
AU - Colin, Estelle
AU - Guichet, Agnès
AU - Bonneau, Dominique
AU - van Jaarsveld, R H
AU - Lachmeijer, A M A
AU - Ruaud, Lyse
AU - Levy, Jonathan
AU - Tabet, Anne-Claude
AU - Ploski, Rafal
AU - Rydzanicz, Małgorzata
AU - Kępczyński, Łukasz
AU - Połatyńska, Katarzyna
AU - Li, Yidan
AU - Fatih, Jawid M
AU - Marafi, Dana
AU - Rosenfeld, Jill A
AU - Coban-Akdemir, Zeynep
AU - Bi, Weimin
AU - Gibbs, Richard A
AU - Hobson, Grace M
AU - Hunter, Jill V
AU - Carvalho, Claudia M B
AU - Posey, Jennifer E
AU - Semina, Elena V
AU - Lupski, James R
N1 - Publisher Copyright:
© 2022 American Society of Human Genetics
PY - 2022/12/1
Y1 - 2022/12/1
N2 - An Xq22.2 region upstream of PLP1 has been proposed to underly a neurological disease trait when deleted in 46,XX females. Deletion mapping revealed that heterozygous deletions encompassing the smallest region of overlap (SRO) spanning six Xq22.2 genes (BEX3, RAB40A, TCEAL4, TCEAL3, TCEAL1, and MORF4L2) associate with an early-onset neurological disease trait (EONDT) consisting of hypotonia, intellectual disability, neurobehavioral abnormalities, and dysmorphic facial features. None of the genes within the SRO have been associated with monogenic disease in OMIM. Through local and international collaborations facilitated by GeneMatcher and Matchmaker Exchange, we have identified and herein report seven de novo variants involving TCEAL1 in seven unrelated families: three hemizygous truncating alleles; one hemizygous missense allele; one heterozygous TCEAL1 full gene deletion; one heterozygous contiguous deletion of TCEAL1, TCEAL3, and TCEAL4; and one heterozygous frameshift variant allele. Variants were identified through exome or genome sequencing with trio analysis or through chromosomal microarray. Comparison with previously reported Xq22 deletions encompassing TCEAL1 identified a more-defined syndrome consisting of hypotonia, abnormal gait, developmental delay/intellectual disability especially affecting expressive language, autistic-like behavior, and mildly dysmorphic facial features. Additional features include strabismus, refractive errors, variable nystagmus, gastroesophageal reflux, constipation, dysmotility, recurrent infections, seizures, and structural brain anomalies. An additional maternally inherited hemizygous missense allele of uncertain significance was identified in a male with hypertonia and spasticity without syndromic features. These data provide evidence that TCEAL1 loss of function causes a neurological rare disease trait involving significant neurological impairment with features overlapping the EONDT phenotype in females with the Xq22 deletion.
AB - An Xq22.2 region upstream of PLP1 has been proposed to underly a neurological disease trait when deleted in 46,XX females. Deletion mapping revealed that heterozygous deletions encompassing the smallest region of overlap (SRO) spanning six Xq22.2 genes (BEX3, RAB40A, TCEAL4, TCEAL3, TCEAL1, and MORF4L2) associate with an early-onset neurological disease trait (EONDT) consisting of hypotonia, intellectual disability, neurobehavioral abnormalities, and dysmorphic facial features. None of the genes within the SRO have been associated with monogenic disease in OMIM. Through local and international collaborations facilitated by GeneMatcher and Matchmaker Exchange, we have identified and herein report seven de novo variants involving TCEAL1 in seven unrelated families: three hemizygous truncating alleles; one hemizygous missense allele; one heterozygous TCEAL1 full gene deletion; one heterozygous contiguous deletion of TCEAL1, TCEAL3, and TCEAL4; and one heterozygous frameshift variant allele. Variants were identified through exome or genome sequencing with trio analysis or through chromosomal microarray. Comparison with previously reported Xq22 deletions encompassing TCEAL1 identified a more-defined syndrome consisting of hypotonia, abnormal gait, developmental delay/intellectual disability especially affecting expressive language, autistic-like behavior, and mildly dysmorphic facial features. Additional features include strabismus, refractive errors, variable nystagmus, gastroesophageal reflux, constipation, dysmotility, recurrent infections, seizures, and structural brain anomalies. An additional maternally inherited hemizygous missense allele of uncertain significance was identified in a male with hypertonia and spasticity without syndromic features. These data provide evidence that TCEAL1 loss of function causes a neurological rare disease trait involving significant neurological impairment with features overlapping the EONDT phenotype in females with the Xq22 deletion.
KW - Autistic Disorder/genetics
KW - Female
KW - Humans
KW - Intellectual Disability/genetics
KW - Male
KW - Muscle Hypotonia/genetics
KW - Phenotype
KW - Syndrome
KW - Transcription Factors/genetics
UR - http://www.scopus.com/inward/record.url?scp=85143379858&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2022.10.007
DO - 10.1016/j.ajhg.2022.10.007
M3 - Article
C2 - 36368327
SN - 0002-9297
VL - 109
SP - 2270
EP - 2282
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 12
ER -